Grail
Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth
Grail shared new results from the NHS trial of its Galleri screening test, which brought in $29.1 million in Q1, a 24 percent increase over the same quarter last year.
Grail, Athenahealth Ink Deal to Facilitate Liquid Biopsy Test Ordering
The integration will enable more than 160,000 US clinicians on the Athenahealth network to "opt in to more seamlessly order Galleri directly in the EHR," Grail said in a statement.
New Grail Publication Explores Optimal Liquid Biopsy MCED Test Interval for Mortality Impact
Premium
Company investigators calculated the expected reduction in late-stage cancer diagnoses and projected drops in mortality for different screening schedules in different models of cancer growth.
360Dx Top 30 Declines 4 Percent in April
Of the 30 companies on the list, 17 saw their stock prices decrease, 11 saw their share prices increase, and two had their stock prices remain flat.
Investment Banks Initiate Coverage of Tempus, Grail
Analysts from BTIG highlighted Tempus' artificial intelligence-based genomics, while Canaccord Genuity underscored Grail's strength in pan-cancer screening.